United States - English - NLM (National Library of Medicine)

mayne pharma commercial llc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older. the safety and effectiveness of calcitriol ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated. none risk summary available data from pregnancies that occurred during the clinical development of calcitriol ointment and published case series of oral and intravenous calcitriol use in pregnant women have not identified a drug associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes. in animal reproduction studies, topical administration of calcitriol to pregnant rabbits during the period of organogenesis resulted in an increased incidence of fetal deaths, as well as an increased incidence of minor skeletal abnormalities (see data) . the available data do not allow the calculation of relevant comparisons between the systemic exposures of calcitriol observed in animal studies t

United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 0.25 ug

United States - English - NLM (National Library of Medicine)

galderma laboratories, l.p. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 3 ug in 1 g - vectical ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older. the safety and effectiveness of vectical ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated. none risk summary available data from pregnancies that occurred during the clinical development of vectical ointment and published case series of oral and intravenous calcitriol use in pregnant women have not identified a drug associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes. in animal reproduction studies, topical administration of calcitriol to pregnant rabbits during the period of organogenesis resulted in an increased incidence of fetal deaths, as well as an increased incidence of minor skeletal abnormalities (see data) . the available data do not allow the calculation of relevant comparisons between the systemic exposures of calcitriol observed in animal studies to the

United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) -

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyro

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - calcitriol -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - calcitriol -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow - sical is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. sical a is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. sical is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: gelatin; butylated hydroxyanisole; glycerol; iron oxide red; iron oxide yellow; titanium dioxide; medium chain triglycerides; butylated hydroxytoluene; maize starch; sorbitol; mannitol - for the management of established post-menopausal osteoporosis by increasing calcium absorption, elevating circulating levels of calcitriol, and reducing vertebral fracture frequency. for the prevention of corticosteriod-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. for the treatment of hypoclacamia in patients with uraemic osteodystrophy, hypoparathyroidism and vitamin d resistant rickets. indications as at 4 march 2004: rocaltrol is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of a traumatic fracture. rocaltrol is also indicated for the prevention of corticosteriod-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. rocaltrol is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphatemic rickets.